Some experts say oral versions of popular weight-loss drugs such as Wegovy could offer people more flexibility and ...

Let's look at why this news could be a game-changer for Eli Lilly and its stock.

Slimlex GLP-1 Capsules in Canada. Natural weight loss support, appetite control & metabolic boost. Buy now from the official ...

As CMS maintains limits on GLP-1 coverage for weight loss, new efficacy data and shifting prescribing patterns point to sustained high demand across the drug class. Here are four updates: 1. Federal ...

Eli Lilly (NYSE: LLY) stock jumped over 14% on Thursday, powered by highly promising Phase 3 results for orforglipron, an ...

Injectables for type 2 diabetes and weight loss could soon be a thing of the past. Eli Lilly announced Thursday the successful completion of a phase 3 trial of Orforglipron – the first small-molecule ...

The drugmaker Lilly announced topline results of a clinical trial of a new pill in the same drug class as injectables like ...

U.S.-listed shares of Novo Nordisk plunged 7% in intraday trading Thursday after rival Eli Lilly reported positive oral ...

Eli Lilly and Co. aired positive top-line data from the phase III trial called Achieve-1 testing orforglipron vs. placebo in adults with type 2 diabetes and inadequate glycemic control with diet and ...

Appetite-suppressing medications that an estimated 10% of American adults use are disrupting grocery shopping.

The mid-stage trial results announced by the pharmaceutical giant showed that patients taking orforglipron lost an average of ...

Eli Lilly (NYSE:LLY) shares climbed ~14% in the premarket on Thursday after the company said its oral GLP-1 receptor agonist ...